While TV viewers love to hear the words, “You’re Fired,” from Donald Trump, few would ever want to have that conversation with their own boss. That is, unless they are the boss and managed to negotiate a hefty separation package. So-called golden parachutes are contractual...
Stocks point modestly higher open today. As investors returned from the long holiday weekend looking for signs that the economy is continuing to Joining me now for more than markets and the rest of the day's business days. Is that Kelly Kirby inside track them Bloomberg television bulletin hi dear
Results reported here Sunday may not put the nail in the coffin for a once wildly popular cholesterol-lowering drug, but they do put Zetia at the bottom of the list of medications that doctors will be using. So said Dr. Anthony DeMaria, a leading cardiologist who is also the editor in chief of the
Here are some of the latest health and medical news developments, compiled by editors of HealthDay: Health Care Workers First to Receive U.S. Swine Flu Shots Doctors, paramedics and other health-care workers in Indiana, Illinois and Tennessee were the first Americans to receive the H1N1 swine flu
FRIDAY, Aug. 14 (HealthDay News) -- The drug Saphris (asenapine) has been approved by the U.S. Food and Drug Administration to treat adults with either schizophrenia or bipolar I disorder, the agency said Friday. Symptoms of schizophrenia may include hearing imagined voices, seeing things that
Shareholders of drugmakers Merck MRK and Schering-Plough SGP on Friday both overwhelmingly backed a $41.1 billion tie-up to create the world's No. 2 pharmaceutical company. The acquisition of smaller Schering-Plough allows Merck, the world's eighth-biggest drugmaker by prescription medicine sales,
Bristol-Myers Squibb said Wednesday it is buying Medarex for about $2.1 billion in cash, the latest in a string of biotechnology acquisitions by the drugmaker. New York-based Bristol-Myers said it will pay $16 a share for Medarex, based in Princeton, N.J. The price represents a 90% premium over
Landmark assessment also finds that treating early helps prevent liver failure.
Companies on Tuesday continued posting second-quarter profits that topped analyst expectations. The reports fostered a renewed sense of optimism in the market. "This is the most solid evidence that we've seen that conditions are improving," said Jack Ablin, chief investment officer at Harris
Drugmaker Merck on Tuesday posted a 12% drop in second-quarter profit, because of lower sales of its cholesterol drugs and several vaccines. The company said the strong dollar was also a factor, lowering total revenue to $5.9 billion. The maker of asthma and allergy treatment Singulair and cervical